The estimated Net Worth of Paul Sauer is at least $2.63 Million dollars as of 22 August 2022. Mr Sauer owns over 3,000 units of Vaxcyte stock worth over $1,667,709 and over the last 4 years he sold PCVX stock worth over $965,186.
Mr has made over 13 trades of the Vaxcyte stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of PCVX stock worth $77,790 on 22 August 2022.
The largest trade he's ever made was selling 6,000 units of Vaxcyte stock on 10 March 2022 worth over $150,000. On average, Mr trades about 2,545 units every 33 days since 2021. As of 22 August 2022 he still owns at least 14,687 units of Vaxcyte stock.
You can see the complete history of Mr Sauer stock trades at the bottom of the page.
Paul W. Sauer M.B.A., MBA is the Sr. VP of Process Devel. & Manufacturing at Vaxcyte.
Mr MBA is 60, he's been the Sr. VP of Process Devel. & Manufacturing of Vaxcyte since . There are no older and 10 younger executives at Vaxcyte.
Paul's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: